GLP-1 drugs like Ozempic and Wegovy are reshaping employer drug spend. Coverage decisions come down to weighing rising costs against outcomes, employee demand, and competitive benefits positioning. Most employers are moving toward conditional coverage models rather than blanket exclusion or inclusion.